Literature DB >> 11508810

Biodistribution of copper carboranyltetraphenylporphyrins in rodents bearing an isogeneic or human neoplasm.

M Miura1, D D Joel, H M Smilowitz, M M Nawrocky, P L Micca, D A Hoch, J A Coderre, D N Slatkin.   

Abstract

The biodistributions of carborane-containing copper porphyrins, CuTCP and CuTCPH, have been studied previously in mice bearing subcutaneously implanted mammary carcinomas. We now report biodistributions of those porphyrins in Fischer 344 rats bearing intracranial and/or multiple subcutaneous isogeneic 9L gliosarcomas (9LGS). The porphyrin was given either by i.v. infusion or by multiple i.p. injections. When 190 mg CuTCPH/kg body weight was given to the rats by i.v. infusion, median tissue boron concentrations (microg/g) 3 days after the end of infusion were: 64 in subcutaneous tumor, 13 in intracranial tumor, 1 in blood and 3 in brain. When 450 mg CuTCPH/kg body weight was given to the rats by serial i.p. injections, the median concentrations (microg B/g) 4 days after the last injection were: 117 in subcutaneous tumor, 50 in intracranial tumor, 4 in blood, and 4 in brain. CuTCPH biodistribution was also studied in xenografts of the human malignant gliomas U87 and U373, and of the murine EMT-6 mammary carcinoma and the rat 9LGS, each grown subcutaneously in mice with severe combined immunodeficiency (SCIDs). In SCIDs, median boron concentrations (microg/g) 2 days after the last s.c. injection of a total of 190 mg CuTCPH/kg body weight were: 251 in U373, 33 in U87, <0.6 in blood and <0.5 in brain. Because there were such high boron levels in the U373, and because xenografted U373 is similar to spontaneous intracerebral human glioblastoma multiforme (GBM) microscopically, CuTCPH could prove useful as a boron carrier for boron neutron-capture therapy (BNCT) of GBM and of other human malignant gliomas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11508810     DOI: 10.1023/a:1010622319892

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  10 in total

1.  Boron neutron capture therapy of intracerebral rat gliosarcomas.

Authors:  D D Joel; R G Fairchild; J A Laissue; S K Saraf; J A Kalef-Ezra; D N Slatkin
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

2.  Effect of dose and infusion time on the delivery of p-boronophenylalanine for neutron capture therapy.

Authors:  D D Joel; J A Coderre; P L Micca; M M Nawrocky
Journal:  J Neurooncol       Date:  1999-02       Impact factor: 4.130

3.  Synthesis of a nickel tetracarboranylphenylporphyrin for boron neutron-capture therapy: biodistribution and toxicity in tumor-bearing mice.

Authors:  M Miura; P L Micca; C D Fisher; J C Heinrichs; J A Donaldson; G C Finkel; D N Slatkin
Journal:  Int J Cancer       Date:  1996-09-27       Impact factor: 7.396

4.  Boron neutron capture therapy of a murine mammary carcinoma using a lipophilic carboranyltetraphenylporphyrin.

Authors:  M Miura; G M Morris; P L Micca; D T Lombardo; K M Youngs; J A Kalef-Ezra; D A Hoch; D N Slatkin; R Ma; J A Coderre
Journal:  Radiat Res       Date:  2001-04       Impact factor: 2.841

5.  Boron neutron capture therapy for glioblastoma multiforme: interim results from the phase I/II dose-escalation studies

Authors: 
Journal:  Neurosurgery       Date:  1999-06       Impact factor: 4.654

Review 6.  The radiation biology of boron neutron capture therapy.

Authors:  J A Coderre; G M Morris
Journal:  Radiat Res       Date:  1999-01       Impact factor: 2.841

7.  Neutron capture therapy of the 9L rat gliosarcoma using the p-boronophenylalanine-fructose complex.

Authors:  J A Coderre; T M Button; P L Micca; C D Fisher; M M Nawrocky; H B Liu
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-10-15       Impact factor: 7.038

8.  Current status of 10B-neutron capture therapy: enhancement of tumor dose via beam filtration and dose rate, and the effects of these parameters on minimum boron content: a theoretical evaluation.

Authors:  R G Fairchild; V P Bond
Journal:  Int J Radiat Oncol Biol Phys       Date:  1985-04       Impact factor: 7.038

9.  Evaluation of carborane-containing porphyrins as tumour targeting agents for boron neutron capture therapy.

Authors:  M Miura; P L Micca; C D Fisher; C R Gordon; J C Heinrichs; D N Slatkin
Journal:  Br J Radiol       Date:  1998-07       Impact factor: 3.039

10.  Microanalytical techniques for boron analysis using the 10B(n,alpha)7Li reaction.

Authors:  R G Fairchild; D Gabel; B H Laster; D Greenberg; W Kiszenick; P L Micca
Journal:  Med Phys       Date:  1986 Jan-Feb       Impact factor: 4.071

  10 in total
  2 in total

1.  Convection enhanced delivery of carboranylporphyrins for neutron capture therapy of brain tumors.

Authors:  Shinji Kawabata; Weilian Yang; Rolf F Barth; Gong Wu; Tianyao Huo; Peter J Binns; Kent J Riley; Owendi Ongayi; Vijay Gottumukkala; M Graça H Vicente
Journal:  J Neurooncol       Date:  2010-09-17       Impact factor: 4.130

2.  Hemorrhage in mouse tumors induced by dodecaborate cluster lipids intended for boron neutron capture therapy.

Authors:  Tanja Schaffran; Nan Jiang; Markus Bergmann; Ekkehard Küstermann; Regine Süss; Rolf Schubert; Franz M Wagner; Doaa Awad; Detlef Gabel
Journal:  Int J Nanomedicine       Date:  2014-07-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.